A recall notice from the U.S. Food and Drug Administration says two types of blood pressure medications are being recalled after tests revealed potentially high levels of a cancer-causing chemical.
The manufacturer, Lupin Pharmaceuticals Inc., is voluntarily recalling its Irbesartan and Hydrochlorothiazide blood pressure tablets at the consumer level, according to reports by SILive.com and Health.com.
“As part of Lupin’s ongoing assessment, analysis revealed that certain tested API batches (but not finished product batches) were above the specification limit for the impurity, N-nitrosoirbesartan,” the FDA says in its recall notice.
“Although Lupin has received no reports of illness that appear to relate to this issue, the company, out of an abundance of caution, is recalling all batches of Irbesartan Tablets USP 75mg, 150mg and 300mg and Irbesartan and Hydrochlorothiazide Tablets USP, 150mg/12.5mg and 300mg/12.5mg in the U.S.,” the FDA says.
Lupin discontinued the marketing of Irbesartan and Irbesartan and HCTZ tablets in January 2021, the FDA noted.
The FDA says Irbesartan and hydrochlorothiazide tablets are packaged in 30- and 90-count bottles and were distributed nationwide in the U.S. to wholesalers, drug chains, mail order pharmacies and supermarkets.
“If you’re currently taking this medication, the FDA recommends that you continue to do so but contact your health care provider about alternatives,” says a report by Health.com.
Our journalism needs your support. Please subscribe today to NJ.com.